Yonit Lavin1, Soma Kobayashi1, Andrew Leader1

  • 1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Cell
|May 6, 2017
PubMed
まとめ

早期の肺腺癌はT細胞とNK細胞の免疫を変化させる. 腫瘍に浸透する骨髄細胞は,抗腫瘍T細胞の反応を損なう可能性があり,免疫療法の設計を導く.